IQVIA (NYSE:IQV) Downgraded to “Hold” Rating by StockNews.com

IQVIA (NYSE:IQV) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Wednesday.

Several other equities analysts have also commented on IQV. William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Truist Financial restated a “buy” rating and set a $263.00 price target (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Leerink Partners restated an “outperform” rating and set a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. JPMorgan Chase & Co. cut their price target on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Finally, Stephens assumed coverage on IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective on the stock. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Stock Performance

IQV stock opened at $183.72 on Wednesday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The business’s fifty day simple moving average is $197.36 and its two-hundred day simple moving average is $211.78. IQVIA has a twelve month low of $179.28 and a twelve month high of $261.72. The firm has a market cap of $32.39 billion, a price-to-earnings ratio of 24.50, a PEG ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Analysts predict that IQVIA will post 10.84 earnings per share for the current year.

Institutional Investors Weigh In On IQVIA

Institutional investors have recently added to or reduced their stakes in the business. Avior Wealth Management LLC boosted its holdings in IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares in the last quarter. Synergy Asset Management LLC acquired a new stake in shares of IQVIA during the fourth quarter worth about $33,000. GKV Capital Management Co. Inc. acquired a new stake in shares of IQVIA during the fourth quarter worth about $39,000. Lee Danner & Bass Inc. acquired a new stake in shares of IQVIA during the fourth quarter worth about $44,000. Finally, Assetmark Inc. lifted its holdings in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.